Scarica l'app Stockscreener
18.94
1.83%
0.34
Dopo l'orario di chiusura:
18.91
-0.03
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$18.60
Aprire:
$19.82
Volume 24 ore:
6.50M
Relative Volume:
1.79
Capitalizzazione di mercato:
$14.07B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-59.19
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
-27.10%
1M Prestazione:
-26.26%
6M Prestazione:
-4.87%
1 anno Prestazione:
-30.90%
Intervallo 1D:
$18.58
$19.97
Intervallo di 1 settimana:
$16.31
$22.78
Portata 52W:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.94 | 13.08B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Acquires 333,394 Shares - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 333,394 Shares - MarketBeat
Summit Therapeutics' (SMMT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Siren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2%Should You Sell? - MarketBeat
Adage Capital Partners GP L.L.C. Invests $10.38 Million in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) Shares Surge After CEO Stock Purchases - GuruFocus
Summit Therapeutics Stock (SMMT) Opinions on HARMONi Trial Data Release - Quiver Quantitative
Summit Therapeutics stock gains on insider buys (SMMT:NASDAQ) - Seeking Alpha
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m By Investing.com - Investing.com Nigeria
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m - Investing.com
Summit Therapeutics director Zanganeh buys shares worth $5.9m - Investing.com
Summit Therapeutics(SMMT.US) 10% Shareholder Buys US$5.98 Million in Common Stock - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating - MSN
Polar Asset Management Partners Inc. Decreases Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Vident Advisory LLC Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - GlobeNewswire Inc.
Summit’s Stock Plunge: What Lies Ahead? - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Summit Therapeutics' (SMMT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions - Yahoo Finance
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
What’s the fair value of Summit Therapeutics Inc. stock2025 Sector Review & High Accuracy Swing Entry Alerts - Lancaster City Council
Summit Therapeutics Inc. Investors: Please contact the - GlobeNewswire
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study - The Globe and Mail
Top 3 Health Care Stocks You'll Regret Missing In Q3 - Benzinga
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
First disclosure of Phase II data for pumitamig - The Pharma Letter
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
Akeso's Lung Cancer Drug Faces US Approval Hurdles - Finimize
Cutter Capital Management LP Acquires New Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingJuly 2025 Highlights & Advanced Technical Analysis Signals - beatles.ru
Summit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT) - MarketBeat
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Summit's High-Profile Drug Flops And Shares Crash - Investor's Business Daily
Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health - TheStreet
Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts - Endpoints News
Top Midday Decliners - MarketScreener
Summit Therapeutics Enters Oversold Territory (SMMT) - Nasdaq
Summit Therapeutics Breaks Below 200-Day Moving AverageNotable for SMMT - Nasdaq
Transcript : Summit Therapeutics Inc.Special Call - MarketScreener
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions - BioSpace
Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward - Seeking Alpha
Summit Therapeutics Shares Plunge After Lung Cancer Drug Data Disappoints - MSN
Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner - Bloomberg.com
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch - MSN
Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics - Yahoo Finance
Summit Therapeutics stock rises as H.C. Wainwright reiterates Buy rating - Investing.com
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):